ClinicalTrials.gg
TerminatedNCT01433978Updated Feb 6, 2018Results posted

A Phase 3, Multicenter, Randomized, Double-blind,Active-controlled, Parallel-group Trial With an Open-labelExtension Phase to Evaluate the Efficacy and Safety of OralE5501 Versus Eltrombopag, in Adults With Chronic ImmuneThrombocytopenia (Idiopathic Thrombocytopenic Purpura)

A Phase 3 interventional study of Eltrombopag and Avatrombopag in Idiopathic Thrombocytopenic Purpura, sponsored by Eisai Inc.. Terminated at 1 site in United States. Open to participants aged 18 Years to 99 Years. Per ClinicalTrials.gov, last updated 2018-02-06.

Sponsored by Eisai Inc. · Phase 3, Interventional, and Treatment

Why this study was terminated
Study was terminated early due to significant enrollment challenges.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
24
Allocation
Randomized
Ages
18 Years to 99 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic — 5 open to participants now, 5 under way, 2 of them phase 3. avatrombopag · Purpura, Thrombocytopenic, Idiopathic.

Enrollment
14th of 16
24 · median 53
Started
2012
with 1 other
Phase 3
6 of 16
1 open now
Registered
5th of 16
by date
Lead sponsor
7 of 16
Eisai Inc.

Among the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, this one is the 14th largest by enrollment, is one of 2 that started in 2012, is one of 6 in phase 3, and was the 5th registered.

Purpura, Thrombocytopenic, Idiopathic

504 studies on the registry are indexed under Purpura, Thrombocytopenic, Idiopathic; 159 are open to participants now.

Browse Purpura, Thrombocytopenic, Idiopathic studies →

Open to participants now

5 of the 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic are open now, in 2 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

About avatrombopag

avatrombopag: first FDA approval 2018 (DOPTELET), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 103 Purpura, Thrombocytopenic, Idiopathic studies recruiting now, 49 (48%) set no upper age limit and 42 (41%) stop at 75 or younger; 27 take children under 18; 4 take healthy volunteers.

This study: 18 Years to 99 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 16 studies testing avatrombopag in Purpura, Thrombocytopenic, Idiopathic, or all of them as a file.
02

Study summary

Core study:

To compare the efficacy of avatrombopag (in addition to standard) of care to eltrombopag (in addition to standard of care) for the treatment of adult participants with chronic immune thrombocytopenia (idiopathic thrombocytopenic purpura [ITP]) as measured by durable platelet response.

Open-label Extension Phase:

To evaluate the safety and tolerability of long-term therapy with avatrombopag in participants with chronic ITP (cITP).

Read the detailed description

The study consists of three phases: Prerandomization, Randomization (Core Study) and Extension Phase. Participants 18 years of age and over, who meet all the eligibility requirements will be randomized into the study. It will require that splenectomized participants make up at least 35% of the study population and no single platelet count is greater than 35x10\^9/L. Participants will be centrally stratified at randomization by splenectomy status, baseline platelet count, and use of concomitant ITP medication at baseline and randomized to receive either double-blind avatrombopag or eltrombopag in a 1:1 ratio. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag once daily or 50 mg eltrombopag once daily. Participants will be allowed to have their dose titrated up (maximum dose 40 mg avatrombopag and 75 mg for eltrombopag) or down (minimum dose 5 mg for avatrombopag and 25 mg for eltrombopag) depending on their response to study drug. The goal of dose modification is to maintain the platelet count at levels greater than or equal to 50x10\^9/L and less than or equal to 150x10\^9/L, and to decrease the need for ITP-directed concomitant medications. The duration of treatment in the Core study and the Extension Phase is approximately 26 and 104 weeks, respectively.

03

Conditions studied

  • Idiopathic Thrombocytopenic Purpura
04

Who can participate

Ages eligible
18 Years to 99 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Men and women greater than or equal to 18 years of age.
  2. Participants diagnosed with cITP (greater than or equal to 12 months duration) according to the American Society for Hematology/British Committee for Standards in Hematology (ASH/BCSH) guidelines, and an average of 2 counts less than 30x10\^9/L). The physical exam should not suggest any disease which may cause thrombocytopenia other than ITP.
  3. Participants who previously received one or more ITP therapies (including, but not limited to , immunoglobulins, azathioprine, danazol, cyclophosphamide and/or rituximab).
  4. Participants must have had either initially responded (platelet count greater than 50x10\^9/L) to a previous ITP therapy or have had a bone marrow examination consistent with ITP within 3 years to rule out myelodysplastic syndrome (MDS) or other causes of thrombocytopenia.
  5. /International Normalized Ratio (PT/INR) and activated partial thromboplastin time (aPTT) must have been within 80% to 120% of the normal range with no history of hypercoagulable state.
  6. A complete blood count within the reference range (including white blood count [WBC] differential not indicative of a disorder other than ITP), with the following exceptions: a) : participants with hemoglobin levels between 10 g/dL (100 g/L) and the lower limit of normal (LLN) are eligible for inclusion, if anemia was clearly attributable to ITP (excessive blood loss); b) (ANC) greater than or equal to 1500/uL (1.5x10\^9/L) (elevated WBC/ANC due to corticosteroid treatment is acceptable).

Exclusion criteria

Exclusion Criteria:

Core Study

  1. Participants with known secondary immune thrombocytopenia (e.g., participants with known Helicobacter pylori-induced ITP, infected with known [HIV] or virus [HCV] or with known systemic lupus erythematosus [SLE]).
  2. Participants considered unable, or unwilling to comply with the study protocol requirements or give , as determined by the investigator.
  3. Participants with significant medical conditions that may impact the safety of the participant or interpretation of the study results (e.g., acute hepatitis, active chronic hepatitis; lymphoproliferative disease; myeloproliferative disorders, leukemia).
  4. History of MDS.
  5. History of pernicious anemia or participants with vitamin B12 deficiency who have not had pernicious anemia excluded as a cause.
  6. Any prior history of arterial or venous thrombosis (stroke, , myocardial infarction, deep vein thrombosis, or pulmonary embolism), and more than two of the following risk factors: estrogen-containing hormone replacement or therapies, smoking, diabetes, hypercholesterolemia, medication for hypertension, cancer, hereditary thrombophilic disorders (e.g., Factor V Leiden, antithrombin III deficiency, etc.), or any other family history of arterial or venous thrombosis.
  7. Participants with a history of significant cardiovascular disease (e.g., congestive heart failure [CHF] Grade III/IV), arrhythmia known to increase the risk of thromboembolic events [e.g., atrial fibrillation], participants with a corrected for heart rate of >450 msec, angina, unstable angina, coronary artery stent placement, angioplasty, or coronary artery bypass grafting).
  8. Participants with a history of cirrhosis, portal hypertension, and chronic active hepatitis.
  9. Participants with concurrent malignant disease.
  10. Use of immunoglobulins (IVIg and anti-D) within 1 week of randomization.
  11. Splenectomy or use of rituximab within 12 weeks of randomization.
  12. Use of romiplostim or eltrombopag within 4 weeks of randomization.
  13. Participants who are currently treated with or azathioprine but have not been receiving a stable dose for at least 4 weeks prior to randomization or have not completed these therapies more than 4 weeks prior to randomization.
  14. Participants who are currently treated with MMF, CsA, or danazol but have not been receiving a stable dose for at least 12 weeks prior to randomization or have not completed these therapies more than 4 weeks prior to randomization.
  15. Use of cyclophosphamide or vinca alkaloid regimens within 4 weeks of randomization.
  16. Participants who are currently treated with PPIs or H2 antagonist therapy but have not been receiving a stable dose for at least 6 weeks prior to randomization or have not completed these therapies more than 2 weeks prior to randomization.
  17. Fasting gastrin-17 blood levels exceeding (including subjects on PPIs and H2 antagonists) at Screening.
  18. Blood creatinine exceeding ULN by more than 20% OR total albumin below the LLN by 10% (revised per Amendment 01).
  19. (ALT) and aspartate aminotransferase (AST) levels exceeding 2 times the ULN; total exceeding 1.5 times the ULN.
  20. Participants with a history of cancer treatment with cytotoxic chemotherapy and/or radiotherapy.
  21. Participants with a history of ITP treatment with cytotoxic chemotherapy are still eligible for enrollment.
  22. Females who are pregnant (positive beta-human chorionic gonadotropin [B-hCG] test) or breastfeeding.
  23. Participants with a known allergy to E5501 or eltrombopag and any of their .
  24. Participants with a history of significant aminotransferase elevations while receiving eltrombopag (defined as ALT and/or AST elevation >3 x ULN).
  25. Participants who are known nonresponders (defined as counts that never exceed 50 x 10\^9/L) to all previous TPO agonist therapy (including previous E5501 therapy) who do not have a bone marrow examination consistent with ITP taken at any point after failure of TPO therapy to rule out MDS or other causes of thrombocytopenia.
Terms in these criteria, in plain language(16)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

TIA (transient ischaemic attack)

A “mini-stroke”: temporary stroke-like symptoms caused by reduced blood flow to part of the brain, spinal cord or eye, without signs of a new stroke on a scan.

Stroke symptoms need emergency care at once, even if they go away.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

QT and QTc

On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.

The study may name a correction formula and a limit in milliseconds, often around 450–480.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
24 participants (actual)

Study arms

  • Active comparator
    Avatrombopag (Core Study)

    Avatrombopag will be administered orally as 5 mg, 10 mg, 20 mg, 30 mg or 40 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 20 mg avatrombopag, once daily and allow to have their dose titrated up (maximum dose of 40 mg avatrombopag) or down (minimum dose of 5 mg avatrombopag) depending on their response to study drug.

    Drug: Avatrombopag · Drug: Standard of care

  • Active comparator
    Eltrombopag (Core Study)

    Eltrombopag will be administered orally as 25 mg, 50 mg, or 75 mg in a flexible dose design for 26 weeks. Participants will receive blinded therapy at a starting dose of 50 mg eltrombopag once daily and allow to have their dose titrated up (maximum dose of 75 mg eltrombopag) or down (minimum dose of 25 mg eltrombopag) depending on their response to study drug.

    Drug: Eltrombopag · Drug: Standard of care

  • Experimental
    Avatrombopag (Open-label Extension)

    Participants who meet the eligibility requirements for the Open-label Extension (OLE) Phase or who discontinue the Core Study early because of lack of treatment effect will be eligible to continue into the OLE Phase for up to 104 weeks of open-label avatrombopag therapy. Participants who enter the OLE from the Core Study will receive a starting dose of open-label avatrombopag which will be determined by the last dose of study drug at the End of Treatment (EOT) Visit (Visit 22) of the Core Study. Participants who discontinue the Core Study early because of lack of treatment effect and enter the OLE will receive open-label avatrombopag at a starting dose of 20 mg once daily of open-label avatrombopag.

    Drug: Avatrombopag · Drug: Standard of care

Interventions

  • Also known as: Promacta, Revolade

  • Also known as: E5501, Avatrombopag maleate

  • DrugStandard of care

    Permitted ITP concomitant background therapies are as follows: * Corticosteroids and/or azathioprine taken at a stable dose for 4 weeks before randomization; * Mycophenolate mofetil (MMF) or danazol taken at a stable dose for at least 12 weeks before randomization; * Cyclosporine A (CsA) (due to the fact that it is a P-glycoprotein-mediated transport \[P-gp\] inhibitor) is to be avoided unless deemed medically necessary; CsA taken at a stable dose for at least 12 weeks before randomization. At the discretion of the investigator, participants will be allowed to use aspirin, other salicylates, or approved adenosine diphosphate (ADP) receptor antagonists, (eg, clopidogrel, prasugrel) during the study once their platelet count had risen. Participants treated with proton pump inhibitors (PPIs) and H2 antagonist therapy will receive a stable dose for at least 6 weeks prior to randomization. Treatment with these therapies must have been completed at least 2 weeks prior to randomization.

06

What researchers measure

Primary outcomes

  1. Change From Baseline in Local Platelet Count for the 6 Month Treatment Period

    Platelet responses to avatrombopag was evaluated using the platelet counts determined at local clinical laboratories. Only participants with non-missing data at both baseline and the relevant post-baseline visit are included in the change from baseline summary statistics. Standard deviation is not applicable for some of the categories, from Visit 14 to Visit 22, as the number of participants analyzed for that visit was 1 individual.

    Time frame: Day 5, Day 8, Week 2, Week 3, Week 4, Week 6, Week 8, Week 10, Week 12, Week 14, Week 16, Week 18, Week 19, Week 20, Week 22, Week 23, Week 24, Week 25, Week 26

07

Results

Posted Feb 6, 2018
Limitations and caveats
Study was terminated early (during the Extension Phase) due to significant enrollment changes.

Participant flow

Core Study
Participant flow — Core Study
MilestoneEltrombopag (Core Study)Avatrombopag (Core Study)Avatrombopag (Open-label Extension Phase)
Started11120
Completed010
Not completed11110
Withdrew: Adverse event, non-fatal010
Withdrew: Lack of efficacy510
Withdrew: Study terminated by sponsor690
Extension Phase
Participant flow — Extension Phase
MilestoneEltrombopag (Core Study)Avatrombopag (Core Study)Avatrombopag (Open-label Extension Phase)
Started006
Completed000
Not completed006
Withdrew: Adverse event, non-fatal001
Withdrew: Lack of efficacy001
Withdrew: Study terminated by sponsor004

Outcome measures

PrimaryChange From Baseline in Local Platelet Count for the 6 Month Treatment Period

Platelet responses to avatrombopag was evaluated using the platelet counts determined at local clinical laboratories. Only participants with non-missing data at both baseline and the relevant post-baseline visit are included in the change from baseline summary statistics. Standard deviation is not applicable for some of the categories, from Visit 14 to Visit 22, as the number of participants analyzed for that visit was 1 individual.

Time frame:
Day 5, Day 8, Week 2, Week 3, Week 4, Week 6, Week 8, Week 10, Week 12, Week 14, Week 16, Week 18, Week 19, Week 20, Week 22, Week 23, Week 24, Week 25, Week 26
Reported as:
Geometric mean · cells x 10^9/L
Change From Baseline in Local Platelet Count for the 6 Month Treatment Period
cells x 10^9/LEltrombopag (Core Study)Avatrombopag (Core Study)
Visit 3 (Day 5)8.60 ± 17.31212.85 ± 16.054
Visit 4 (Day 8)32.50 ± 44.51947.00 ± 59.690
Visit 5 (Week 2)73.41 ± 79.885171.71 ± 201.736
Visit 6 (Week 3)67.20 ± 95.536114.21 ± 117.172
Visit 7 (Week 4)28.72 ± 38.437108.79 ± 217.036
Visit 8 (Week 6)57.21 ± 57.718150.68 ± 134.902
Visit 9 (Week 8)67.25 ± 46.055121.31 ± 149.040
Visit 10 (Week 10)92.67 ± 34.649126.25 ± 90.602
Visit 11 (Week 12)87.33 ± 72.616185.10 ± 115.841
Visit 12 (Week 14 )104.33 ± 77.114159.38 ± 116.746
Visit 13 (Week 16)47.75 ± 2.475123.88 ± 124.474
Visit 14 (Week 18)107.50 ± NA46.50 ± 53.740
Visit 15 (Week 19)13.50 ± NA29.50 ± 22.627
Visit 16 (Week 20)—50.50 ± NA
Visit 18 (Week 22)—75.50 ± NA
Visit 19 (Week 23)—104.50 ± NA
Visit 20 (Week 24)—106.50 ± NA
Visit 21 (Week 25)—120.50 ± NA
Visit 22 (Week 26)—58.50 ± NA

Adverse events

Collected over Up to 34 Weeks in the Core Study (including Titration, Treatment, Dose Taper, and Follow-up for those that did not enter the Extension Phase) and up to 112 weeks in the Extension Phase (including Conversion, Maintenance, Dose Taper, and Follow-up).. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Eltrombopag (Core Study)—0/11 (0%)11/11 (100%)
Avatrombopag (Core Study)—2/12 (16.7%)11/12 (91.7%)
Avatrombopag (Extension Phase)—4/17 (23.5%)16/17 (94.1%)
Most frequent serious events
Most frequent serious events
EventEltrombopag (Core Study)Avatrombopag (Core Study)Avatrombopag (Extension Phase)
Idiopathic thrombocytopenic purpuraBlood and lymphatic system disorders0/111/121/17
Portal vein thrombosisHepatobiliary disorders0/111/121/17
Bronchitis MoraxellaInfections and infestations0/111/121/17
Thrombophlebitis SepticInfections and infestations0/111/121/17
Chronic obstructive pulmonary diseaseRespiratory, thoracic and mediastinal disorders0/111/121/17
PneumothoraxRespiratory, thoracic and mediastinal disorders0/111/121/17
InfluenzaInfections and infestations0/110/121/17
Chronic lymphotic leukaemiaNeoplasms benign, malignant and unspecified (incl cysts and polyps)0/110/121/17
Most frequent other events
Showing 10 of 96
Most frequent other events
EventEltrombopag (Core Study)Avatrombopag (Core Study)Avatrombopag (Extension Phase)
FatigueGeneral disorders5/111/125/17
HeadacheNervous system disorders3/113/125/17
DiarrhoeaGastrointestinal disorders3/112/122/17
NasopharyngitisInfections and infestations3/112/124/17
NauseaGastrointestinal disorders2/113/123/17
Musculoskeletal painMusculoskeletal and connective tissue disorders0/113/123/17
DizzinessNervous system disorders2/113/124/17
InsomniaPsychiatric disorders1/113/124/17
ContusionInjury, poisoning and procedural complications2/110/121/17
ArthralgiaMusculoskeletal and connective tissue disorders2/111/122/17

Baseline characteristics

Safety analysis set included all participants who received at least one dose of study treatment and at least one postbaseline safety assessment.

Age, Continuous
Age, Continuous(Years)Eltrombopag (Core Study)Avatrombopag (Core Study)Total
Geometric mean45.4 ± 20.0950.8 ± 23.0448.2 ± 21.36
Sex: Female, Male
Sex: Female, Male(Participants)Eltrombopag (Core Study)Avatrombopag (Core Study)Total
Female7714
Male459
08

Study locations

1 site
  • Prairie Lakes Health Care System
    Watertown, South Dakota, United States
09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Mar 2012 to primary completion in Sep 2013, 18 months.

Results were first posted in Feb 2018, 4 years 5 months after primary completion. A results delay was requested in Jun 2015.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 13, 2011
First posted
Sep 14, 2011
StartActual
Mar 26, 2012
Primary completionActual
Sep 2013
CompletionActual
Sep 2013
Results delay requested
Jun 29, 2015
Results first posted
Feb 6, 2018
Last update
Feb 6, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 6, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT01433978
Lead sponsor
Eisai Inc.
Responsible party
Sponsor
First posted
Sep 14, 2011
Start date
Mar 26, 2012
Primary completion
Sep 2013
Completion
Sep 2013
Results posted
Feb 6, 2018
Last update
Feb 6, 2018

Study contacts

Joe McIntosh
study director · Eisai Inc.

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Avatrombopag

Start the discussion